Drugs / Humanized CD25 antibody
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05923814 | Jul 2023 → May 2024 | — | Institute of Hematology & Blood Diseases Hospital, China | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Humanized CD25 antibody | “The humanized CD25 antibody was administered at 1 mg/kg iv on days+1 and +4 after HSCT.” NCT05923814 ↗ |
| Route | Intravenous | “administered at 1 mg/kg iv” NCT05923814 ↗ |